###begin article-title 0
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse models of breast cancer metastasis
###end article-title 0
###begin p 1
###xml 78 86 <span type="species:ncbi:9606">patients</span>
###xml 330 335 <span type="species:ncbi:10090">mouse</span>
###xml 459 463 <span type="species:ncbi:10090">mice</span>
###xml 503 508 <span type="species:ncbi:10090">mouse</span>
Metastatic spread of cancer cells is the main cause of death of breast cancer patients, and elucidation of the molecular mechanisms underlying this process is a major focus in cancer research. The identification of appropriate therapeutic targets and proof-of-concept experimentation involves an increasing number of experimental mouse models, including spontaneous and chemically induced carcinogenesis, tumor transplantation, and transgenic and/or knockout mice. Here we give a progress report on how mouse models have contributed to our understanding of the molecular processes underlying breast cancer metastasis and on how such experimentation can open new avenues to the development of innovative cancer therapy.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
###xml 118 119 118 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 310 311 310 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 312 313 312 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 735 736 735 736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 737 738 737 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 111 116 <span type="species:ncbi:9606">women</span>
Breast cancer is the most frequently diagnosed form of cancer and the second leading cause of death in Western women [1]. Death, and most of the complications associated with breast cancer, are due to metastasis developing in regional lymph nodes and in distant organs, including bone, lung, liver, and brain [1,2]. As in many other metastatic cancer types, specific molecular changes occurring within both the tumor cells and the tumor microenvironment contribute to the detachment of tumor cells from the primary tumor mass, invasion into the tumor stroma, intravasation into nearby blood vessels or lymphatics, survival in the bloodstream, extravasation into and colonization of the target organ and, finally, metastatic outgrowth [3,4].
###end p 3
###begin p 4
###xml 140 145 <span type="species:ncbi:10090">mouse</span>
###xml 234 239 <span type="species:ncbi:10090">mouse</span>
In the recent past, our understanding of breast cancer progression and metastasis has greatly profited from the use of genetically modified mouse models and advanced transplantation techniques. Here we describe the currently employed mouse models of breast cancer metastasis and how their use has contributed significantly to our understanding of the molecular processes underlying breast cancer metastasis.
###end p 4
###begin title 5
Mechanisms contributing to breast cancer metastasis
###end title 5
###begin p 6
###xml 42 47 <span type="species:ncbi:10090">mouse</span>
A critical step towards the generation of mouse models of breast cancer is the understanding of the molecular pathways underlying mammary carcinogenesis. Our knowledge on how breast tumor progression occurs has also been markedly improved by unraveling the dynamics and the key factors of mammary gland development.
###end p 6
###begin title 7
Mammary gland development
###end title 7
###begin p 8
###xml 209 210 209 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 312 313 312 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1013 1014 1013 1014 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse breast tissue undergoes continuous changes throughout the lifespan of reproductively active females, mediated mainly by interactions between the mammary epithelium and the surrounding mesenchyme (Figure 1). The mammary bud develops by forming a network of branched ducts invading into the mammary fat pad [5]. With the release of ovarian hormones, terminal end buds are formed. They represent the invading front of the ducts and they are able to proliferate, to extend into the fat pad, and to form branches. During pregnancy and lactation, hormone-induced terminal differentiation of the mammary epithelium into milk-secreting lobular alveoli takes place. After weaning, the secretory epithelium of the mammary gland involutes into an adult nulliparous-like state by apoptosis and redifferentiation. During these processes, the developing mammary gland has the ability to induce angiogenesis to adjust for blood supply and is protected against premature involution; it is therefore resistant to apoptosis [6]. Interestingly, proliferation, invasion, angio-genesis, and resistance to apoptosis are all features that are abused during the etiology of breast carcinogenesis.
###end p 8
###begin title 9
Transformation and metastasis
###end title 9
###begin p 10
###xml 148 149 148 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 196 197 190 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 238 239 232 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 288 290 282 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 864 865 858 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1558 1560 1552 1554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1561 1563 1555 1557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
Mammary gland morphogenesis and branching involve the regulatory function of several signaling pathways, including signaling by Wnt family members [7], transforming growth factor-beta (TGF-beta) [8], insulin-like growth factor-I (IGF-I) [9], and epidermal growth factor (EGF) and others [10]. These pathways are frequently activated during the tumorigenic process by mutation or gene amplification, thus allowing the mammary epithelium to expand, proliferate, and invade neighboring tissue. The cross-talk and interactions between tumor cells and the surrounding stroma, the extracellular matrix (ECM), and infiltrating cells of the immune system are constantly modulating tumor development. The mammary stroma, composed of pre-adipocytes, adipocytes, fibroblasts, endo-thelial cells, and inflammatory cells, contributes functionally to mammary gland development [6]. In a similar manner, tumor-stroma interactions, occurring via soluble growth factors, cytokines and chemokines, remodeling of the extra-cellular matrix, or direct cell-cell adhesion, are critical for tumor growth, migration, and metastasis. Alteration of the expression or function of adhesion molecules responsible for the adhesion of breast cancer cells to themselves, to stromal cells, or to tumor matrix, including integrin family members, immunoglobulin-domain cell adhesion molecules (such as L1 and NCAM), cadherin family members, or other cell surface receptors (such as CD44), contributes predominantly to late-stage tumor progression and metastatic dissemination of cancer cells [11,12].
###end p 10
###begin p 11
###xml 530 532 530 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 662 664 662 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 863 865 863 865 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1004 1016 <span type="species:ncbi:9606">participants</span>
The formation of new blood vessels (angiogenesis) is crucial for the growth and persistence of primary solid tumors and their metastases, and it has been assumed that angiogenesis is also required for metastatic dissemination, because an increase in vascular density will allow easier access of tumor cells to the circulation. Induction of angiogenesis precedes the formation of malignant tumors, and increased vascularization seems to correlate with the invasive properties of tumors and thus with the malignant tumor phenotype [13]. In fact, angiogenesis indicates poor prognosis and increased risk of metastasis in many cancer types, including breast cancer [14]. With the recent identification of lymphangiogenic factors and their receptors it has also been possible to investigate the causal role of lymphangiogenesis in the metastatic process (reviewed in [15]). It is therefore not surprising that molecules essential for mammary gland development, many of them stromal factors, are also critical participants in breast carcinogenesis.
###end p 11
###begin p 12
###xml 123 128 <span type="species:ncbi:10090">mouse</span>
The knowledge gained on the several mechanisms contributing to tumor progression can be used to design and generate better mouse models. At the same time, such models allow a thorough investigation of all different aspects of multistage breast carcinogenesis, including the genetic alterations leading to tumor onset, neovascularization, tumor progression, and formation of metastasis in secondary organs.
###end p 12
###begin title 13
Breast cancer metastasis models
###end title 13
###begin title 14
Tumor transplantation
###end title 14
###begin p 15
###xml 530 532 530 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 520 528 <span type="species:ncbi:9606">patients</span>
There are various ways to mimic breast cancer growth and metastasis in tumor transplantation experiments. The site of injection, together with the specific tropism of the chosen breast cancer cell line used, largely defines primary and secondary metastatic growth. Orthotopic or ectotopic implantation of cancer cells in the skin or mammary fat pad, with the formation of primary tumors and the subsequent formation of metastasis, in part resembles the multiple stages involved in malignant breast cancer development in patients [16]. In contrast, tail vein injection results mainly in lung metastasis, whereas portal vein injection provokes colonization of the liver, and intracardiac infusion gives rise to a broader target organ spectrum, including bone. Notably, the direct introduction of cancer cells into the blood circulation should be considered an assay of organ colonization and not a true metastatic process.
###end p 15
###begin p 16
###xml 441 443 441 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 444 446 444 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 638 646 638 646 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 647 649 647 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 874 876 874 876 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 877 879 877 879 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1456 1458 1456 1458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1619 1621 1619 1621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1622 1624 1622 1624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 179 184 <span type="species:ncbi:10090">mouse</span>
###xml 198 203 <span type="species:ncbi:10090">mouse</span>
###xml 459 464 <span type="species:ncbi:10090">mouse</span>
###xml 719 724 <span type="species:ncbi:10090">mouse</span>
###xml 751 756 <span type="species:ncbi:10090">mouse</span>
###xml 1486 1491 <span type="species:ncbi:10090">mouse</span>
Depending on the species or genetic background of donor and host, syngeneic or xenograft tumor transplantations need to be distinguished. Transplantation of cancer cells from one mouse into another mouse with identical genetic backgrounds (syngeneic transplantation) bypasses the immunologic host-versus-graft reaction and concomitantly allows the investigation of the contribution of an intact immune system to malignant tumor progression [17,18]. Syngeneic mouse models have been employed to establish organ-specific metastasis models by several rounds of transplantation/metastasis formation and the selection of metastatic cell lines in vivo [19]. For example, 4T1 cells, which originally derive from a spontaneous mouse mammary tumor of a BALB/C mouse, grow rapidly when injected into the fat pad of a syngeneic animal and metastasize to lungs, liver, bone, and brain [19,20]. Sublines of 4T1 cells, which exhibit various degrees of metastatic dissemination, have been employed recently to generate distinct gene expression signatures for each stage of tumor progression, namely primary tumor formation, lymph node colonization, metastatic outgrowth in the lymph node, and distant organ metastasis. These experiments led to the identification of the transcriptional repressor Twist, some members of the cadherin family of cell-cell adhesion molecules, and various chemokines as critical factors in the distinct stages of metastatic tumor progression [20]. This and other syngeneic mouse models have also been successfully employed for the testing of experimental drugs designed to interfere with tumor malignancy [18,21].
###end p 16
###begin p 17
###xml 75 82 75 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 163 165 163 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 306 308 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 546 548 546 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 826 828 826 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 829 831 829 831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 988 990 988 990 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 44 49 <span type="species:ncbi:9606">human</span>
###xml 157 161 <span type="species:ncbi:10090">mice</span>
###xml 168 173 <span type="species:ncbi:9606">Human</span>
###xml 299 304 <span type="species:ncbi:10090">mouse</span>
###xml 436 443 <span type="species:ncbi:9606">patient</span>
To investigate the growth and metastasis of human breast cancer cell lines in vivo, xenograft transplantation experiments are performed in immunocompromised mice [22]. Human breast cancer cells can be injected subcutaneously, intravenously, intracardially, or orthotopically into the fat pad of the mouse [23]. For example, MDA-MB-231 cells, an estrogen-independent breast cancer cell line derived from the pleural effusion of a cancer patient, is able to colonize bone, liver, lung, adrenal glands, ovary, and brain after intravenous injection [24]. This cell line and organ-specific metastatic variants thereof have recently been used to identify and functionally implicate a number of genes in organ-specific metastasis, including IL-11, osteopontin and the connective tissue growth factor (CTGF) in osteolytic metastasis [25,26], and epiregulin, CXCL1, matrix metalloproteinase-1 (MMP-1), cyclo-oxygenase-2 (COX-2), inhibitor of differentiation-1 (Id1) and others in lung metastasis [27] (see below).
###end p 17
###begin p 18
###xml 833 835 833 835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 836 838 836 838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1136 1138 1136 1138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 56 61 <span type="species:ncbi:9606">human</span>
###xml 341 345 <span type="species:ncbi:10090">mice</span>
###xml 474 481 <span type="species:ncbi:9606">patient</span>
###xml 578 583 <span type="species:ncbi:10090">mouse</span>
###xml 847 852 <span type="species:ncbi:9606">human</span>
###xml 905 911 <span type="species:ncbi:10090">murine</span>
###xml 1021 1026 <span type="species:ncbi:10090">mouse</span>
###xml 1122 1127 <span type="species:ncbi:9606">human</span>
###xml 1217 1222 <span type="species:ncbi:9606">human</span>
The implantation of established cell lines derived from human breast cancer is relatively simple and allows the genetic or pharmacological manipulation of the implanted cells. However, there are clear limitations to xenograft models. First, immune responses, which have a key role during tumor development, are impaired in immunocompromised mice. Second, stromal components are not of tumor origin. For example, carcinoma-associated fibroblasts derived from a breast cancer patient support the growth of a breast carcinoma cell line better than the normal tissue in a xenograft mouse co-implantation model. Carcinoma-associated fibroblasts seem to activate and sustain CXCR4/stromal cell-derived factor (SDF-1)-mediated chemokine signaling and to recruit endothelial progenitors to the growing tumor, thereby promoting angiogenesis [28,29]. Last, human cells are apparently not fully adapted to grow in a murine environment. For example, breast cancer metastasis to bone has recently been investigated in an experimental mouse system in which both the breast cancer cells and the metastatic target organ, the bone, are of human origin [30]. After orthotopic injection, cancer cells predominantly colonize the bone of human origin, thus exhibiting a species-specific osteotropism.
###end p 18
###begin title 19
###xml 21 25 <span type="species:ncbi:10090">mice</span>
Genetically modified mice
###end title 19
###begin p 20
###xml 101 102 101 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 690 692 686 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 693 695 689 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 991 993 983 985 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 1106 1107 1098 1099 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 219 223 <span type="species:ncbi:10090">mice</span>
###xml 279 294 <span type="species:ncbi:10633">simian virus 40</span>
###xml 296 300 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 350 354 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 363 367 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 373 388 <span type="species:ncbi:10090">transgenic mice</span>
###xml 447 452 <span type="species:ncbi:10090">Mouse</span>
###xml 575 590 <span type="species:ncbi:10090">transgenic mice</span>
###xml 630 645 <span type="species:ncbi:10090">transgenic mice</span>
###xml 704 708 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 719 734 <span type="species:ncbi:10090">transgenic mice</span>
###xml 970 975 <span type="species:ncbi:9606">human</span>
###xml 1030 1035 <span type="species:ncbi:10090">mouse</span>
Several promoters can be used to drive the expression of transgenes in the mammary epithelium (Table 1), and many known oncogenes have been expressed under their control to initiate or modulate breast carcinogenesis in mice, including ErbB2/Neu, polyoma middle T antigen (PyMT), simian virus 40 (SV40) T antigen, Ha-Ras, Wnt-1, TGF-alpha, and c-Myc. MMTV-Neu and MMTV-PyMT transgenic mice (in which the expression of the oncogene is driven by the Mouse Mammary Tumor Virus promoter) develop metastasis in lung and lymph nodes, mainly after their first pregnancy, while other transgenic mice have to be combined to generate double-transgenic mice that efficiently develop malignant cancers [31-35]. C3(1)-SV40 T-antigen transgenic mice develop invasive mammary carcinomas independently of hormone supplementation or pregnancy, with a 15% incidence of lung metastasis. This model recapitulates the loss of estrogen receptor-alpha expression that is frequently observed in human breast cancer [36]. The most commonly used transgenic mouse models that develop metastatic mammary cancer are summarized in Table 2.
###end p 20
###begin p 21
###xml 171 173 171 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 408 410 408 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 615 617 615 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 882 884 873 875 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 426 430 <span type="species:ncbi:10090">mice</span>
###xml 788 792 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
Investigating the functional role of distinct genes during the multiple stages of breast carcinogenesis requires the ability to modulate their function in time and space [37]. Inducible transgene expression can be obtained by the use of the bacteria-derived tetracycline-inducible system permitting the switching on or off (Tet-On/Tet-Off system) of a gene of interest in a tissue- and time-specific manner [38]. In contrast, mice are modified by the genetic ablation of a gene of interest in an inducible manner to generate conditional knockouts with the use of the Cre/loxP phage recombinase system, for example [39]. To ablate a gene at a certain time point in mammary epithelial cells, recombinase activity can be controlled by the expression of a tamoxifen-inducible version of Cre (MMTV-ERtrade mark-Cre) or by using the tetracycline-inducible system to drive Cre expression [40].
###end p 21
###begin p 22
###xml 242 244 242 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 201 206 <span type="species:ncbi:9606">human</span>
###xml 347 354 <span type="species:ncbi:9606">patient</span>
###xml 420 425 <span type="species:ncbi:10090">mouse</span>
###xml 472 476 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 485 489 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 495 500 <span type="species:ncbi:10090">mouse</span>
First comparisons of gene expression profiles obtained from mammary gland tumor models initiated by different oncogenes have revealed several common and oncogene-specific targets and similarities with human molecular breast cancer pathology [41]. The challenge now is to test whether genes identified in gene expression profiling experiments with patient samples are able to modulate breast carcinogenesis in transgenic mouse models, for example in the well-characterized MMTV-Neu and MMTV-PyMT mouse models of breast carcinogenesis or in improved versions of these.
###end p 22
###begin title 23
###xml 0 4 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
MMTV-Neu
###end title 23
###begin p 24
###xml 502 504 502 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 116 121 <span type="species:ncbi:9606">human</span>
###xml 334 337 <span type="species:ncbi:10116">rat</span>
###xml 364 368 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 373 388 <span type="species:ncbi:10090">transgenic mice</span>
Amplification of the gene encoding ErbB2, a member of the EGF receptor gene family, is associated with 15 to 20% of human breast cancers, and in about 30% of cases the increased expression of an activated form of ErbB2 is detected. Consistent with this notion is the observation that transgenic expression of an activated form of the rat homolog of ErbB2 (Neu) in MMTV-Neu transgenic mice results in the development of multifocal adenocarcinomas with lung metastases at about 15 weeks after pregnancy [42]. Transgenic expression of wild-type ErbB2 in mammary gland also provokes tumor formation and metastatic dissemination, yet with longer latency.
###end p 24
###begin p 25
###xml 305 307 305 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 839 841 839 841 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 73 88 <span type="species:ncbi:10090">transgenic mice</span>
###xml 265 269 <span type="species:ncbi:10090">mice</span>
###xml 556 561 <span type="species:ncbi:9606">human</span>
Doxycycline-inducible expression of ErbB2 in mammary epithelial cells of transgenic mice also results in invasive mammary carcinoma and extensive metastasis, yet the tumors regress with the loss of ErbB2 expression upon the withdrawal of doxycycline. However, most mice exhibit recurrences of the tumors [43]. These recurrent tumors exhibit epithelial-mesenchymal transition (EMT), which seems to be mediated by the upregulated expression of the transcriptional repressor Snail, a molecular process that seems to have a high prognostic value in predicting human breast cancer recurrence. Expression of oncogenic versions of ErbB2 that bind either Grb-2 or Shc demonstrate that focal mammary tumors with a high rate of lung metastasis require Grb-2-mediated signaling, whereas low metastatic multifocal mammary tumors rely on Shc function [44].
###end p 25
###begin title 26
###xml 0 4 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
MMTV-PyMT
###end title 26
###begin p 27
###xml 305 307 305 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 476 478 476 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 771 773 768 770 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 67 71 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 93 108 <span type="species:ncbi:10090">transgenic mice</span>
###xml 110 114 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 351 355 <span type="species:ncbi:10090">mice</span>
###xml 519 524 <span type="species:ncbi:9606">human</span>
###xml 585 589 <span type="species:ncbi:10090">mice</span>
###xml 780 784 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 790 795 <span type="species:ncbi:10090">mouse</span>
Mammary gland-specific expression of PyMT under the control of the MMTV promoter/enhancer in transgenic mice (MMTV-PyMT) results in widespread transformation of the mammary epithelium and in the development of multifocal mammary adenocarcinomas and metastatic lesions in the lymph nodes and in the lungs [45]. Tumor formation and progression in these mice is characterized by four stages: hyperplasia, adenoma/mammary intra-epithelial neoplasia, and early and late carcinoma [46]. The close similarity of this model to human breast cancer is also exemplified by the fact that in these mice a gradual loss of steroid hormone receptors (estrogen and progesterone) and beta1-integrin is associated with overexpression of ErbB2 and cyclin D1 in late-stage metastatic cancer [47]. The MMTV-PyMT mouse model of breast cancer is furthermore characterized by short latency, high penetrance, and a high incidence of lung metastasis occurring independently of pregnancy and with a reproducible kinetics of progression.
###end p 27
###begin p 28
###xml 288 290 288 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 291 293 291 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 314 318 314 318 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 449 451 449 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 452 454 452 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 799 801 799 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 802 804 802 804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 1359 1361 1359 1361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 3 7 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 13 28 <span type="species:ncbi:10090">transgenic mice</span>
###xml 299 303 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 318 322 <span type="species:ncbi:10090">mice</span>
###xml 737 741 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 747 752 <span type="species:ncbi:10090">mouse</span>
###xml 979 983 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 989 993 <span type="species:ncbi:10090">mice</span>
###xml 1213 1217 <span type="species:ncbi:10090">mice</span>
In MMTV-PyMT transgenic mice, increased metastatic potential has been shown to depend on the presence of macrophages in primary tumors and on the establishment of a chemoattractant paracrine loop of colony-stimulating factor-1 (CSF-1) and EGF ligands between macrophages and tumor cells [48,49]. In MMTV-PyMT/CSF-1-/- mice, tumor progression and metastasis are significantly delayed but restored on the overexpression of CSF-1 in the mammary gland [48,50]. The crucial role of macrophages in sustaining tumor progression was further shown by depletion of plasminogen, a downstream effector of CSF-1, either by its genetic ablation or by affecting the expression of its activator uPA, resulting in significantly reduced metastasis in the MMTV-PyMT mouse model without affecting primary tumor growth [51,52]. The uPA/plasminogen system may contribute to metastasis mainly by ECM degradation. The relevance of this mechanism is further supported by experiments with MEKK1-deficient MMTV-PyMT mice, which show a significant delay in lung metastasis, whereas no differences are observed in the primary tumor growth. MEKK1 signaling is involved in cell adhesion and controls uPA induction. Accordingly, MEKK1-deficient mice display decreased levels of uPA, which result in reduced levels of activated plasminogen and impaired tumor cell migration and invasiveness [53].
###end p 28
###begin p 29
###xml 270 272 270 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 704 706 701 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 110 114 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 120 124 <span type="species:ncbi:10090">mice</span>
###xml 187 191 <span type="species:ncbi:10090">mice</span>
###xml 468 472 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
The role of adhesion molecules during mammary gland tumor progression has also been addressed with the use of MMTV-PyMT mice. Specifically, loss of CD44 promotes lung metastasis in these mice, highlighting the role of tumor-stroma interaction for adhesion and invasion [12]. CD44 expression on tumor cells mediates their interaction with hyaluronan-expressing stromal cells and results in increased cancer progression. Loss of another adhesion molecule, Muc-1, in the MMTV-Wnt1 tumor model results in a delayed onset of tumorigenesis as well as delayed metastasis to lungs. Muc-1 seems to form complexes with beta-catenin at the cell membrane and in the cytoplasm of cells at the tumor's invading front [54].
###end p 29
###begin p 30
###xml 101 103 101 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 642 647 <span type="species:ncbi:10090">mouse</span>
###xml 749 754 <span type="species:ncbi:9606">human</span>
###xml 880 885 <span type="species:ncbi:10090">mouse</span>
Recent results indicate that changes in cell adhesion have a critical function in tumor progression [11]. For example, the epithelial adherens junction molecule E-cadherin is considered a tumor and invasion suppressor. Forced expression of E-cadherin prevents tumor cell migration and invasion, whereas inhibition of E-cadherin function enhances tumor cell invasion and metastatic dissemination. E-cadherin is irreversibly lost in more than 85% of invasive lobular breast cancer associated with an invasive phenotype, and in the remaining 15% the retention of E-cadherin is associated with dysfunctional adhesion. Interestingly, a transgenic mouse model of epithelial loss of both E-cadherin and p53 develops metastatic mammary carcinoma resembling human invasive lobular breast cancer (J. Jonkers, personal communication). Taken together, these examples indicate that transgenic mouse models of breast cancer metastasis are essential to understanding the role of several molecules in modulating key steps during malignant progression.
###end p 30
###begin title 31
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vivo </italic>
In vivo imaging
###end title 31
###begin p 32
###xml 13 21 13 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 583 585 583 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 586 588 586 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 747 749 747 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
###xml 958 960 958 960 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 961 963 961 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 1037 1039 1037 1039 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B62">62</xref>
###xml 1040 1042 1040 1042 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B63">63</xref>
###xml 1045 1053 1045 1053 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 1069 1071 1069 1071 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B64">64</xref>
###xml 136 151 <span type="species:ncbi:10090">transgenic mice</span>
###xml 335 339 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 382 386 <span type="species:ncbi:10090">mice</span>
###xml 390 394 <span type="species:ncbi:10090">mice</span>
###xml 548 552 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 557 561 <span type="species:ncbi:10090">mice</span>
###xml 709 713 <span type="species:ncbi:10090">mice</span>
###xml 733 738 <span type="species:ncbi:10090">mouse</span>
Non-invasive in vivo imaging techniques have been developed to reveal metastatic mammary tumors in experimental systems. Cell lines and transgenic mice can be engineered to express luminescent or fluorescent markers, permitting the visualization of primary tumor growth and the formation of metastatic nodes in live animals over time. MMTV-enhanced green fluorescent protein (eGFP) mice or mice in which expression of eGFP or luciferase marker genes is 'switched on' in the mammary gland in a Cre-dependent way upon crossing with either WAP-Cre or MMTV-Cre mice have been generated [55-57]. Tumor growth and metastasis formation can be easily monitored in composite transgenic animals after crossing of these mice with breast cancer mouse models [58]. Moreover, tumor progression and the actual metastatic mobility of tumor cells can be detected in live animals by multiphoton microscopy, positron-enhanced tomography scans, and magnetic resonance analysis [59-61]. Furthermore, the newest technologies, including intravital microscopy [62,63], in vivo flow cytometry [64], and multicolor fluorescent-based approaches, provide the possibility of quantitatively detecting individual tumor cells in living animals and documenting their clearance, motility, and migration to or retention in target organs.
###end p 32
###begin title 33
###xml 49 54 <span type="species:ncbi:10090">mouse</span>
Molecular pathways dissected using breast cancer mouse models
###end title 33
###begin title 34
Transforming growth factor-beta
###end title 34
###begin p 35
###xml 262 263 259 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 532 534 526 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B65">65</xref>
###xml 762 764 750 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B66">66</xref>
###xml 765 767 753 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B67">67</xref>
###xml 911 913 893 895 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B68">68</xref>
###xml 1122 1124 1098 1100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 1270 1272 1243 1245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B69">69</xref>
###xml 1770 1772 1734 1736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B70">70</xref>
###xml 2098 2100 2053 2055 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B71">71</xref>
###xml 582 586 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 591 595 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 606 610 <span type="species:ncbi:10090">mice</span>
###xml 825 829 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 835 850 <span type="species:ncbi:10090">transgenic mice</span>
###xml 916 931 <span type="species:ncbi:10090">Transgenic mice</span>
###xml 1025 1029 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 1052 1056 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 1061 1065 <span type="species:ncbi:10090">mice</span>
###xml 1210 1214 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 1220 1225 <span type="species:ncbi:10090">mouse</span>
###xml 1306 1311 <span type="species:ncbi:10090">mouse</span>
###xml 1519 1523 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 1528 1532 <span type="species:ncbi:10090">mice</span>
###xml 1580 1584 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 1589 1593 <span type="species:ncbi:10090">mice</span>
###xml 1828 1832 <span type="species:ncbi:10090">mice</span>
TGF-beta exerts a dual role during tumor progression: by inducing the expression of cell cycle inhibitors, it acts as a tumor suppressor during the initial phases of tumor progression. Yet it promotes metastasis and invasion in the later stages by inducing EMT [8]. The role of TGF-beta in breast cancer metastasis is still under investigation. One of its major functions, beside the induction of EMT, is inducing the migration and intravasation of breast cancer cells into the circulation, thereby promoting osteolytic metastasis [65]. Expression of TGF-beta1 in double-transgenic MMTV-Neu/MMTV-TGF-beta1 mice increased the number of cancer cells circulating in the blood as well as the lung metastases, whereas primary tumors developed at unchanged frequency [66,67]. Inducible expression of TGF-beta1 in mammary glands of MMTV-PyMT transgenic mice also demonstrated the pro-metastatic function of TGF-beta1 [68]. Transgenic mice expressing TGF-betaRI or a dominant-negative version of TGF-betaRII under the control of the MMTV promoter crossed with MMTV-Neu mice promoted and repressed, respectively, tumor metastasis [44]. Surprisingly, conditional knockout of TGF-betaRII in the mammary epithelium of the MMTV-PyMT mouse resulted in increased metastasis formation [69]. Together, these experiments in mouse models demonstrate the pivotal role of TGF-beta signaling in breast carcinogenesis. These observations have implications for the development of anti-metastatic therapies. For example, long-term treatment of MMTV-Neu mice with a soluble version of TGF-betaRII protects MMTV-Neu mice from metastasis without increasing primary tumor growth, hence selectively blocking the metastatic effects of TGF-beta while not affecting its functions in early tumor stages [70]. Chronic exposure to the soluble TGF-betaRII in these mice did not cause any unwanted side effects, suggesting a potential avenue for the development of therapy. Small inhibitors of the TGF-beta receptor kinase activity and agents specifically blocking TGF-beta-mediated signaling pathways are currently in clinical trials [71].
###end p 35
###begin title 36
EGF family members
###end title 36
###begin p 37
###xml 648 650 625 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B72">72</xref>
###xml 443 458 <span type="species:ncbi:10090">transgenic mice</span>
###xml 464 468 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 473 488 <span type="species:ncbi:10090">transgenic mice</span>
###xml 501 505 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 516 520 <span type="species:ncbi:10090">mice</span>
###xml 569 573 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 585 589 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 599 603 <span type="species:ncbi:10090">mice</span>
The importance of TGF-alpha, an EGF family member, in mammary tumor onset has been demonstrated by the transgenic expression of TGF-alpha under the control of several mammary epithelium-specific promoters. Such tissue-specific expression has led to distorted mammary gland development. However, primary tumors and pulmonary metastasis formed only after the combination of several additional tumor-promoting factors, such as crossing TGF-alpha transgenic mice with MMTV-Myc transgenic mice or treating MMTV-TGF-alpha mice with chemical carcinogens. In double-transgenic MMTV-TGF-alpha; MMTV-TGF-beta mice, tumor development is, however, suppressed [72].
###end p 37
###begin p 38
###xml 215 217 215 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B73">73</xref>
###xml 478 480 478 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 481 483 481 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B74">74</xref>
###xml 484 486 484 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B75">75</xref>
###xml 851 853 851 853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B76">76</xref>
###xml 1021 1023 1021 1023 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 220 224 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 229 233 <span type="species:ncbi:10090">mice</span>
###xml 556 559 <span type="species:ncbi:10116">rat</span>
###xml 619 623 <span type="species:ncbi:10090">mice</span>
We have already introduced the importance of ErbB2 in breast carcinogenesis. In addition, amplification of the gene encoding EGFR correlates with increased metastasis and is a bad prognosis factor in breast cancer [73]. MMTV-Neu mice have also been extensively employed to investigate the functional contribution of EGFR to mammary carcinogenesis. EGFR-mediated signaling contributes to invasion, intra-vasation and metastasis, along with the mitogenic signaling in this model [49,74,75]. Moreover, EGFR contribution to metastasis was shown by using MTLn3 rat mammary adeno-carcinoma cells injected into the fat pad of mice. By quantifying the number of tumor cells in the blood as a direct measure of cell intravasation it was possible to show that EGFR acts via increased cell motility and intravasation rather then by affecting cell proliferation [76]. A neutralizing antibody against ErbB2 (Herceptin) has been developed to repress the tumorigenic stimuli of ErB2 and has been approved for clinical use (reviewed in [10]). Together with newly developed inhibitors of EGFR signaling, combinatorial repression of EGFR and ErbB2 activity may therefore be an efficient way to combat breast cancer.
###end p 38
###begin title 39
Wnt signaling
###end title 39
###begin p 40
###xml 268 269 268 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 620 622 607 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B77">77</xref>
###xml 73 77 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 174 189 <span type="species:ncbi:10090">transgenic mice</span>
###xml 342 346 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 424 428 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 435 439 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 572 576 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 588 592 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 602 606 <span type="species:ncbi:10090">mice</span>
Wnt family members were the first proto-oncogenes to be discovered by an MMTV-mediated insertion-activation mechanism. Transgenic expression of Wnt-1 in the mammary gland of transgenic mice results in mammary adeno-carcinomas with metastasis to lymph nodes and lungs [7]. Moreover, Wnt-1 collaborates with fibroblast growth factor-3, another MMTV-insertion-activated gene, in tumor onset. Surprisingly, in double-transgenic MMTV-Wnt-1;MMTV-TGF-beta animals, tumor cell proliferation is not repressed by TGF-beta expression, showing an opposite effect to that observed for MMTV-TGF-alpha; MMTV-TGF-beta mice (see above) [77].
###end p 40
###begin title 41
Genes involved in organ-specific metastasis
###end title 41
###begin p 42
###xml 563 565 563 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B78">78</xref>
###xml 566 568 566 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B79">79</xref>
###xml 726 728 726 728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B80">80</xref>
Cancers developing in a certain organ usually exhibit particular patterns of organ-specific metastasis. Breast cancer predominantly colonizes bone, followed by axillary and other lymph nodes, lung, liver, brain, and (rarely) adrenal glands. A combination of physical factors, such as lymphatic and blood vessel capillary networks encountered by disseminating tumor cells, and environmental factors, such as chemo-attractive cytokines or chemokines and the presence of 'vasculature addresses', contribute to the specific dissemination of metastastic cancer cells [78,79]. One possible underlying mechanism is that breast cancer cells follow a cytokine gradient by co-opting immune cells' strategies to arrive at target organs [80].
###end p 42
###begin p 43
###xml 553 555 553 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B80">80</xref>
###xml 556 558 556 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B82">82</xref>
###xml 742 744 742 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 745 747 745 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1355 1357 1355 1357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1358 1360 1358 1360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
Xenograft transplantation experiments using the MDA-MB-231 cell line have been instrumental in demonstrating the functional role of certain genes in organ-specific breast cancer metastasis. For instance, prevention of CXCR4 expression by using short interfering RNA technology or blocking its function with specific antibodies or synthetic peptides repressed the formation of lung metastasis, indicating that the CXCR4 ligand, SDF-1, expressed by metastatic target organs, is recruiting tumor cells via CXCR4, which is expressed on breast cancer cells [80-82]. Orthotopic, intracardiac, and tail vein injections of MDA-MB-231 cells have also been performed to identify genes modulating organ-specific metastasis, for example to bone or lung [25,27]. Gene expression profiling experiments with sublines of MDA-MB-231 selected for organ-specific metastasis have identified specific gene expression signatures for different organ-specific metastases. The functional involvement of these genes and factors in directing organ-specific metastasis was demonstrated subsequently. Genes involved in lung metastasis include those encoding the EGF-like factor epiregulin, CXCL1, MMP-1 and MMP-2, SPARC, vascular cell adhesion molecule-1 (VCAM-1), Id1, and COX-2, and genes promoting bone metastasis include those encoding IL-11, osteopontin, CTGF, CXCR4, and MMP-1 [25,27].
###end p 43
###begin p 44
###xml 165 167 165 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 363 365 363 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B83">83</xref>
###xml 607 609 607 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B74">74</xref>
###xml 778 780 778 780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B84">84</xref>
Overexpression of osteopontin induces metastasis of poorly metastatic MDA-MB-231 cells, whereas its downregulation is correlated with reduced osteolytic metastasis [26]. Osteo-pontin upregulates uPA plasminogen activator, which, upon binding to integrins and surface receptors, provokes the activation of both the hepatocyte growth factor (HGF) and EGF pathways [83]. Xenograft transplantation of MT2994 primary breast cancer cells has shown that the expression of osteopontin was associated with a constitutive activation of the phosphoinositide 3-kinase pathway and a metastatic phenotype of tumor cells [74]. Moreover, osteopontin can induce the expression of alternatively spliced isoforms v6 and v9 of CD44 in breast cancer cells, leading to an increase in cell migration [84].
###end p 44
###begin p 45
###xml 331 333 331 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B85">85</xref>
###xml 522 524 522 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B86">86</xref>
In a similar approach, sublines of the breast cancer cell line MDA-MB-435 have been selected for specific colonization of lung, lymph node, and thorax. Several adhesion and matrix molecules are correlated with lymph node metastasis, including CD73, a cell surface protein previously implicated in lymphocyte homing to lymph nodes [85]. Moreover, MDA-MB-468 variant metastatic cells with tropism to lymph nodes may use differential expression of adhesion molecules and may mimic angiogenesis pathways to reach lymph nodes [86]. Notably, these cells express alpha9beta1 integrin, an integrin that is specifically expressed on lymphatic endothelial cells and can bind many ligands previously implicated in metastasis, including osteopontin, tenascin C, VCAM-1 and the lymphangiogenic factors vascular endothelial growth factor (VEGF)-C and VEGF-D.
###end p 45
###begin p 46
###xml 417 419 417 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B87">87</xref>
###xml 557 565 557 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 566 568 566 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B88">88</xref>
###xml 846 848 846 848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B89">89</xref>
###xml 1080 1082 1080 1082 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B90">90</xref>
###xml 271 275 <span type="species:ncbi:10090">mice</span>
Recent work has documented a role for RANK/RANK ligand (RANKL) signaling together with parathyroid hormone-related protein (PTHrP) and osteoprotegerin in bone metastasis. Treatment with a humanized antibody against PTHrP significantly suppressed osteolytic metastasis in mice injected with a subline of MDA-MB-231 that showed high metastatic ability to bone and expressed high levels of PTHrP, IL-8, IL-6, and MMP-1 [87]. The importance of the role of RANK/RANKL signaling in the regulation of tumor cell migration has also been reported for melanoma cells in vivo [88], whereas experiments performed with MDA-MB-231 breast cancer cells have shown that the RANK soluble receptor, osteoprotegerin, is effective in specifically decreasing bone metastasis by preventing the signaling that mediates the differentiation and activation of osteoclasts [89]. However, in an intra-tibial ectotopic injection model of osteoprotegerin and PTHrP overexpression by MCF-7 breast cancer cells it was revealed that overexpression of osteoprotegerin by tumor cells actually supports tumor growth [90].
###end p 46
###begin p 47
###xml 367 369 367 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 724 726 724 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B91">91</xref>
###xml 926 928 926 928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B92">92</xref>
###xml 1214 1216 1214 1216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B93">93</xref>
###xml 1217 1219 1217 1219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B94">94</xref>
###xml 1561 1563 1561 1563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B95">95</xref>
###xml 154 162 <span type="species:ncbi:9606">patients</span>
###xml 249 254 <span type="species:ncbi:10090">mouse</span>
###xml 610 614 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 620 624 <span type="species:ncbi:10090">mice</span>
###xml 984 989 <span type="species:ncbi:9606">human</span>
Upregulated expression of VEGF-C, and to a smaller extent that of VEGF-D, is highly correlated with lymphangiogenesis and lymph node metastasis in cancer patients. Moreover, forced expression of VEGF-C or VEGF-D in tumor cell lines or in transgenic mouse models of tumorigenesis results in upregulated lymphangiogenesis and in the formation of lymph node metastasis [15]. The role of lymphangiogenesis and angiogenesis in breast cancer metastasis is a major focus of current research. Mammary overexpression of the blood vessel angiogenic factor VEGF-A markedly accelerates the formation of lung metastasis in MMTV-PyMT mice, not only by promoting tumor angiogenesis but also by sustaining tumor proliferation and survival [91]. In a xenograft tumor transplantation model using MDA-MB-231 breast cancer cell line variants with brain tropism, the formation of brain metastases seems highly dependent on the presence of VEGF-A [92]. Moreover, in orthotopic xenograft transplantation of human breast cancer cells with high or low metastatic ability (MDA-MB-435 and MCF-7, respectively), overexpression of VEGF-C induces intra-tumoral lymphoangiogenesis and the subsequent formation of lymph node and lung metastasis [93,94]. Blockade of VEGF receptor-3 signaling by specific antibodies inhibits regional and distant lymph node metastasis in these models, whereas VEGF receptor-2 inhibition results in a suppression of angiogenesis and tumor growth. Notably, a combination of the two treatments suppresses the formation of metastases better than single treatments [95]. These results indicate that angiogenic and lymphangiogenic factors may have central roles in defining organ-specific breast cancer metastasis.
###end p 47
###begin title 48
Conclusion
###end title 48
###begin p 49
###xml 121 126 <span type="species:ncbi:10090">mouse</span>
###xml 328 333 <span type="species:ncbi:10090">mouse</span>
###xml 408 413 <span type="species:ncbi:9606">human</span>
###xml 418 423 <span type="species:ncbi:10090">mouse</span>
###xml 819 823 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 833 837 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 842 846 <span type="species:ncbi:10090">mice</span>
###xml 943 948 <span type="species:ncbi:9606">human</span>
Elucidation of the molecular mechanisms underlying breast cancer progression and metastasis has gained tremendously from mouse models in which the multiple stages of tumor progression are recapitulated. However, despite their obvious convenience in basic cancer research and in the testing of experimental therapies, the use of mouse models carries several limitations. There are obvious differences between human and mouse tumorigenesis, among which are the kinetics of carcinogenesis and the final size of tumors, differences in cell intrinsic features such as the requirements to transform cells, and differences in organ-specific gene expression, in physiology, metabolism, pathology, and in the immune system. Moreover, metastatic dissemination occurs mainly via hematogenous spreading to lungs and lymph nodes in MMTV-PyMT and MMTV-Neu mice, as opposed to the initial spreading of cancer cells to local lymph nodes via the lymphatics in human breast cancer.
###end p 49
###begin p 50
###xml 318 322 <span type="species:ncbi:10090">mice</span>
Another important aspect to the understanding of breast cancer metastasis is the role of different subpopulations of breast cells, including cancer stem cells. A great effort is put into their isolation by means of molecular markers or functional assays. The use of transplanted breast cancer stem cells isolated from mice harboring different genetic modifications thereby offers a valuable tool not only in the unraveling of breast cancer development but also in designing effective therapeutic strategies.
###end p 50
###begin p 51
###xml 223 231 223 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 402 410 402 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 755 763 755 763 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 689 697 <span type="species:ncbi:9606">patients</span>
###xml 807 812 <span type="species:ncbi:10090">mouse</span>
Recent technological advances have greatly improved the use of animal models in breast cancer research, such as the use of bioluminescence and fluorescence systems, magnetic resonance, positron-enhanced tomography scans or in vivo confocal analysis to image tumor development in live animals, also allowing observation for long periods. Moreover, extended time-lapse observation of labeled tumor cells in vivo provides new insights into the actual dynamics of tumor growth, extravasation, cell migration, and organ colonization, as well as the contribution of the tumor stroma and subsets of immune cells. Finally, gene expression analysis of tumor samples matched with normal tissue from patients will provide gene signatures that will have to be tested in vivo by proof-of-concept experiments in reliable mouse models of breast cancer metastasis.
###end p 51
###begin p 52
###xml 47 52 <span type="species:ncbi:10090">mouse</span>
###xml 94 99 <span type="species:ncbi:9606">human</span>
In the future it will be necessary to generate mouse models that more accurately recapitulate human breast carcino-genesis, while offering the advantages of model systems, such as easy genetic or pharmacological manipulation and imaging. The quest for such improved models has just begun.
###end p 52
###begin title 53
Abbreviations
###end title 53
###begin p 54
###xml 317 321 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 324 330 <span type="species:ncbi:10090">murine</span>
COX = cyclo-oxygenase; CSF = colony-stimulating factor; CTGF = connective tissue growth factor; ECM = extracellular matrix; EGF = epidermal growth factor; EMT = epithelial-mesenchymal transition; IGF = insulin-like growth factor; IL = interleukin; MEKK = MAP kinase/ERK kinase kinase; MMP = matrix metalloproteinase; MMTV = murine mammary tumour virus; PTHrP = parathyroid hormone-related protein; PyMT = polyoma middle T antigen; SDF = stromal cell-derived factor; TGF = transforming growth factor; VCAM = vascular cell adhesion molecule; VEGF = vascular endothe-lial growth factor.
###end p 54
###begin title 55
Competing interests
###end title 55
###begin p 56
The authors declare that they have no competing interests.
###end p 56
###begin title 57
Acknowledgements
###end title 57
###begin p 58
We are grateful to Dr Miguel Cabrita and Dr Francois Lehembre for critical comments on the manuscript, and to Dr Jos Jonkers for sharing unpublished results. Research in the laboratory of the authors is supported by the Krebsliga Beider Basel, Novartis Pharma Inc., NCCR Molecular Oncology, the Swiss National Science Foundation and the EU-FP6 framework programs LYMPHANGIOGENOMICS LSHG-CT-2004-503573 and BRECOSM LSHC-CT-2004-503224.
###end p 58
###begin article-title 59
Breast cancer metastasis: markers and models
###end article-title 59
###begin article-title 60
###xml 66 74 <span type="species:ncbi:9606">patients</span>
Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update
###end article-title 60
###begin article-title 61
Dissemination and growth of cancer cells in metastatic sites
###end article-title 61
###begin article-title 62
The hallmarks of cancer
###end article-title 62
###begin article-title 63
###xml 45 50 <span type="species:ncbi:10090">mouse</span>
Think globally, act locally: the making of a mouse mammary gland
###end article-title 63
###begin article-title 64
Stromal effects on mammary gland development and breast cancer
###end article-title 64
###begin article-title 65
###xml 7 11 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 18 33 <span type="species:ncbi:10090">transgenic mice</span>
Use of MMTV-Wnt-1 transgenic mice for studying the genetic basis of breast cancer
###end article-title 65
###begin article-title 66
Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer
###end article-title 66
###begin article-title 67
Insulin-like growth factors and neoplasia
###end article-title 67
###begin article-title 68
ERBB receptors and cancer: the complexity of targeted inhibitors
###end article-title 68
###begin article-title 69
Cell adhesion and signalling by cad-herins and Ig-CAMs in cancer
###end article-title 69
###begin article-title 70
CD44 attenuates metastatic invasion during breast cancer progression
###end article-title 70
###begin article-title 71
Angiogenesis as a therapeutic target
###end article-title 71
###begin article-title 72
###xml 54 62 <span type="species:ncbi:9606">patients</span>
Tumoural vascularity as a prognostic factor in cancer patients: the evidence continues to grow
###end article-title 72
###begin article-title 73
###xml 37 42 <span type="species:ncbi:9606">human</span>
Lymphangiogenesis in development and human disease
###end article-title 73
###begin article-title 74
Modeling metastasis in vivo
###end article-title 74
###begin article-title 75
###xml 62 66 <span type="species:ncbi:10090">mice</span>
Behavior of metastatic and nonmetastatic breast tumors in old mice
###end article-title 75
###begin article-title 76
###xml 40 46 <span type="species:ncbi:10090">murine</span>
From genetic abnormality to metastases: murine models of breast cancer and their use in the development of anticancer therapies
###end article-title 76
###begin article-title 77
###xml 118 123 <span type="species:ncbi:10090">mouse</span>
Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor
###end article-title 77
###begin article-title 78
Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis
###end article-title 78
###begin article-title 79
###xml 39 43 <span type="species:ncbi:10090">mice</span>
Regression of high-grade malignancy in mice by bleomycin and interleukin-12 electrochemo-genetherapy
###end article-title 79
###begin article-title 80
###xml 30 35 <span type="species:ncbi:9606">human</span>
A novel model of a metastatic human breast tumour xenograft line
###end article-title 80
###begin article-title 81
###xml 36 41 <span type="species:ncbi:9606">human</span>
Models of breast cancer: is merging human and animal models the future?
###end article-title 81
###begin article-title 82
Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma
###end article-title 82
###begin article-title 83
A multigenic program mediating breast cancer metastasis to bone
###end article-title 83
###begin article-title 84
###xml 134 139 <span type="species:ncbi:9606">human</span>
Downregulation of osteopon-tin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells
###end article-title 84
###begin article-title 85
Genes that mediate breast cancer metastasis to lung
###end article-title 85
###begin article-title 86
###xml 40 45 <span type="species:ncbi:9606">human</span>
Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion
###end article-title 86
###begin article-title 87
CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation
###end article-title 87
###begin article-title 88
###xml 2 7 <span type="species:ncbi:10090">mouse</span>
###xml 17 22 <span type="species:ncbi:9606">human</span>
###xml 51 56 <span type="species:ncbi:9606">human</span>
A mouse model of human breast cancer metastasis to human bone
###end article-title 88
###begin article-title 89
###xml 39 54 <span type="species:ncbi:10090">transgenic mice</span>
Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes
###end article-title 89
###begin article-title 90
###xml 52 67 <span type="species:ncbi:10090">transgenic mice</span>
Targeted c-myc gene expression in mammary glands of transgenic mice induces mammary tumours with constitutive milk protein gene transcription
###end article-title 90
###begin article-title 91
###xml 130 145 <span type="species:ncbi:10090">transgenic mice</span>
Inhibition of mammary gland involution is associated with transforming growth factor alpha but not c-myc-induced tumorigenesis in transgenic mice
###end article-title 91
###begin article-title 92
###xml 48 52 <span type="species:ncbi:10090">mice</span>
The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting
###end article-title 92
###begin article-title 93
###xml 16 20 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 34 38 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 54 69 <span type="species:ncbi:10090">transgenic mice</span>
Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo
###end article-title 93
###begin article-title 94
###xml 10 14 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 36 41 <span type="species:ncbi:10090">mouse</span>
The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma
###end article-title 94
###begin article-title 95
Tight control of gene expression in mammalian cells by tetracycline-responsive promoters
###end article-title 95
###begin article-title 96
A novel doxycycline-inducible system for the transgenic analysis of mammary gland biology
###end article-title 96
###begin article-title 97
Cre-stimulated recombination at loxP-containing DNA sequences placed into the mammalian genome
###end article-title 97
###begin article-title 98
Cre-mediated gene deletion in the mammary gland
###end article-title 98
###begin article-title 99
###xml 66 71 <span type="species:ncbi:9606">human</span>
Initiating oncogenic event determines gene-expression patterns of human breast cancer models
###end article-title 99
###begin article-title 100
###xml 51 66 <span type="species:ncbi:10090">transgenic mice</span>
Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene
###end article-title 100
###begin article-title 101
The transcriptional repressor Snail promotes mammary tumor recurrence
###end article-title 101
###begin article-title 102
###xml 114 119 <span type="species:ncbi:9606">human</span>
Grb2 and Shc adapter proteins play distinct roles in Neu (ErbB-2)-induced mammary tumorigenesis: implications for human breast cancer
###end article-title 102
###begin article-title 103
###xml 91 96 <span type="species:ncbi:10090">mouse</span>
Induction of mammary tumors by expression of polyomavirus middle T oncogene: a trans-genic mouse model for metastatic disease
###end article-title 103
###begin article-title 104
###xml 63 68 <span type="species:ncbi:10090">mouse</span>
###xml 119 124 <span type="species:ncbi:9606">human</span>
Progression to malignancy in the polyoma middle T oncopro-tein mouse breast cancer model provides a reliable model for human diseases
###end article-title 104
###begin article-title 105
###xml 28 32 <span type="species:ncbi:10090">mice</span>
Transgenic Polyoma middle-T mice model premalignant mammary disease
###end article-title 105
###begin article-title 106
Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy
###end article-title 106
###begin article-title 107
A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors
###end article-title 107
###begin article-title 108
Postnatal mammary gland development requires macrophages and eosinophils
###end article-title 108
###begin article-title 109
###xml 71 75 <span type="species:ncbi:10090">mice</span>
Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice
###end article-title 109
###begin article-title 110
###xml 101 105 <span type="species:ncbi:10090">mice</span>
Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice
###end article-title 110
###begin article-title 111
MEKK1 controls matrix degradation and tumor cell dissemination during metastasis of polyoma middle-T driven mammary cancer
###end article-title 111
###begin article-title 112
MUC1 alters beta-catenin-dependent tumor formation and promotes cellular invasion
###end article-title 112
###begin article-title 113
###xml 52 56 <span type="species:ncbi:10090">mice</span>
Green fluorescent protein imaging of tumor cells in mice
###end article-title 113
###begin article-title 114
###xml 74 89 <span type="species:ncbi:10090">transgenic mice</span>
GFP expression in the mammary gland for imaging of mammary tumor cells in transgenic mice
###end article-title 114
###begin article-title 115
###xml 117 121 <span type="species:ncbi:10090">mice</span>
The generation of a conditional reporter that enables bioluminescence imaging of Cre/loxP-dependent tumorigenesis in mice
###end article-title 115
###begin article-title 116
###xml 17 22 <span type="species:ncbi:10090">mouse</span>
A novel reporter mouse strain that expresses enhanced green fluorescent protein upon Cre-mediated recombination
###end article-title 116
###begin article-title 117
Quantitative imaging of the T cell antitumor response by positron-emission tomography
###end article-title 117
###begin article-title 118
Cellular expression of green fluorescent protein, coupled with high-resolution in vivo videomicroscopy, to monitor steps in tumor metastasis
###end article-title 118
###begin article-title 119
Visualizing the kinetics of tumor-cell clearance in living animals
###end article-title 119
###begin article-title 120
Intravital imaging of cell movement in tumours
###end article-title 120
###begin article-title 121
Steps in tumor metastasis: new concepts from intravital videomicroscopy
###end article-title 121
###begin article-title 122
In vivo flow cytometry: a new method for enumerating circulating cancer cells
###end article-title 122
###begin article-title 123
TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development
###end article-title 123
###begin article-title 124
Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor beta1
###end article-title 124
###begin article-title 125
Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis
###end article-title 125
###begin article-title 126
Conditional overexpression of active transforming growth factor beta1 in vivo accelerates metastases of transgenic mammary tumors
###end article-title 126
###begin article-title 127
Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis
###end article-title 127
###begin article-title 128
###xml 60 64 <span type="species:ncbi:10090">mice</span>
Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects
###end article-title 128
###begin article-title 129
###xml 44 49 <span type="species:ncbi:9606">human</span>
Targeting the TGF beta signaling network in human neoplasia
###end article-title 129
###begin article-title 130
Mammary tumor suppression by transforming growth factor beta 1 transgene expression
###end article-title 130
###begin article-title 131
The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy
###end article-title 131
###begin article-title 132
Growth factor signaling induces metastasis genes in transformed cells: molecular connection between Akt kinase and osteopontin in breast cancer
###end article-title 132
###begin article-title 133
ErbB3-dependent motility and intravasation in breast cancer metastasis
###end article-title 133
###begin article-title 134
Epidermal growth factor receptor overexpression results in increased tumor cell motility in vivo coordinately with enhanced intravasation and metastasis
###end article-title 134
###begin article-title 135
###xml 108 123 <span type="species:ncbi:10090">transgenic mice</span>
Transgenes expressing the Wnt-1 and int-2 proto-oncogenes cooperate during mammary carcinogenesis in doubly transgenic mice
###end article-title 135
###begin article-title 136
Molecular addresses in blood vessels as targets for therapy
###end article-title 136
###begin article-title 137
The organ microenvironment and cancer metastasis
###end article-title 137
###begin article-title 138
Involvement of chemokine receptors in breast cancer metastasis
###end article-title 138
###begin article-title 139
Silencing of CXCR4 blocks breast cancer metastasis
###end article-title 139
###begin article-title 140
Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4
###end article-title 140
###begin article-title 141
###xml 83 88 <span type="species:ncbi:9606">human</span>
Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells
###end article-title 141
###begin article-title 142
Enhanced cell surface CD44 variant (v6, v9) expression by osteopontin in breast cancer epithelial cells facilitates tumor cell migration: novel post-transcriptional, post-translational regulation
###end article-title 142
###begin article-title 143
Gene expression profiling of tumor xenografts: in vivo analysis of organ-specific metastasis
###end article-title 143
###begin article-title 144
###xml 81 86 <span type="species:ncbi:9606">human</span>
A new model for lymphatic metastasis: development of a variant of the MDA-MB-468 human breast cancer cell line that aggressively metastasizes to lymph nodes
###end article-title 144
###begin article-title 145
###xml 115 120 <span type="species:ncbi:9606">human</span>
Humanized monoclonal antibody against parathyroid hormone-related protein suppresses osteolytic bone metastasis of human breast cancer cells derived from MDA-MB-231
###end article-title 145
###begin article-title 146
Regulation of cancer cell migration and bone metastasis by RANKL
###end article-title 146
###begin article-title 147
###xml 94 99 <span type="species:ncbi:10090">mouse</span>
Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis
###end article-title 147
###begin article-title 148
Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically
###end article-title 148
###begin article-title 149
###xml 44 59 <span type="species:ncbi:10090">transgenic mice</span>
VEGF contributes to mammary tumor growth in transgenic mice through paracrine and autocrine mechanisms
###end article-title 149
###begin article-title 150
###xml 103 112 <span type="species:ncbi:10090">nude mice</span>
Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice
###end article-title 150
###begin article-title 151
Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis
###end article-title 151
###begin article-title 152
VEGF-C induced lymphangiogenesis is associated with lymph node metastasis in orthotopic MCF-7 tumors
###end article-title 152
###begin article-title 153
Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2
###end article-title 153
###begin article-title 154
The mammary gland as a bioreactor: production of foreign proteins in milk
###end article-title 154
###begin article-title 155
###xml 121 136 <span type="species:ncbi:10090">transgenic mice</span>
A 470 bp WAP-promoter fragment confers lactation independent, progesterone regulated mammary-specific gene expression in transgenic mice
###end article-title 155
###begin article-title 156
Characterization of the gene encoding ovine beta-lactoglobulin. Similarity to the genes for retinol binding protein and other secretory proteins
###end article-title 156
###begin article-title 157
###xml 57 72 <span type="species:ncbi:10090">transgenic mice</span>
###xml 84 89 <span type="species:ncbi:9606">human</span>
Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E
###end article-title 157
###begin article-title 158
###xml 36 41 <span type="species:ncbi:10090">mouse</span>
###xml 93 108 <span type="species:ncbi:10090">transgenic mice</span>
Distal regulatory elements from the mouse metallothionein locus stimulate gene expression in transgenic mice
###end article-title 158
###begin article-title 159
###xml 77 92 <span type="species:ncbi:10090">transgenic mice</span>
Overexpression of cyclooxyge-nase-2 is sufficient to induce tumorigenesis in transgenic mice
###end article-title 159
###begin article-title 160
###xml 65 80 <span type="species:ncbi:10090">transgenic mice</span>
Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease
###end article-title 160
###begin article-title 161
###xml 71 75 <span type="species:ncbi:10090">mice</span>
Conditional activation of Neu in the mammary epithelium of trans-genic mice results in reversible pulmonary metastasis
###end article-title 161
###begin article-title 162
The mutationally activated Met receptor mediates motility and metastasis
###end article-title 162
###begin article-title 163
###xml 39 54 <span type="species:ncbi:10090">transgenic mice</span>
###xml 66 69 <span type="species:ncbi:10116">rat</span>
###xml 76 91 <span type="species:ncbi:10633">simian virus 40</span>
Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene
###end article-title 163
###begin article-title 164
Expression of a truncated Int3 gene in developing secretory mammary epithelium specifically retards lobular differentiation resulting in tumorigenesis
###end article-title 164
###begin article-title 165
###xml 13 18 <span type="species:ncbi:10090">mouse</span>
A transgenic mouse model for the ductal carcinoma in situ (DCIS) of the mammary gland
###end article-title 165
###begin article-title 166
###xml 55 70 <span type="species:ncbi:10090">transgenic mice</span>
###xml 84 89 <span type="species:ncbi:9606">human</span>
Histopathology of salivary and mammary gland tumors in transgenic mice expressing a human Ha-ras oncogene
###end article-title 166
###begin article-title 167
###xml 33 38 <span type="species:ncbi:10090">mouse</span>
Targeted expression of HGF/SF in mouse mammary epithelium leads to metastatic adenosquamous carcinomas through the activation of multiple signal transduction pathways
###end article-title 167
###begin article-title 168
###xml 55 70 <span type="species:ncbi:10090">transgenic mice</span>
Metastasizing mammary carcinomas in H19 enhancers-Igf2 transgenic mice
###end article-title 168
###begin article-title 169
###xml 80 85 <span type="species:ncbi:10090">mouse</span>
Somatic mutation of p53 leads to estrogen receptor alpha-positive and -negative mouse mammary tumors with high frequency of metastasis
###end article-title 169
###begin article-title 170
P53 levels determine outcome during beta-catenin tumor initiation and metastasis in the mammary gland and male germ cells
###end article-title 170
###begin article-title 171
###xml 59 63 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 68 83 <span type="species:ncbi:10090">transgenic mice</span>
Expression of the calcium-binding protein S100A4 (p9Ka) in MMTV-neu transgenic mice induces metastasis of mammary tumours
###end article-title 171
###begin title 172
Figures and Tables
###end title 172
###begin p 173
Schematic representation of epithelial-stromal interactions during mammary gland development. The mammary bud originates at the embryonic level and starts proliferating after birth. Pubertal hormones drive the invasion of the fat pad by the generation of epithelial ducts and terminal end buds (TEB). Proliferation and side branching continues until epithelial ducts fill the adult mammary gland. Pregnancy hormones induce the full development and proliferation of the mammary gland and the transformation of the lobular alveoli into milk-secreting ducts. After lactation the mammary gland involutes to return to a nulliparous-like state via apoptosis, redifferentiation and remodeling processes. C/EBP, CCAAT-enhancer-binding protein; CSF, colony-stimulating factor; DDR, discoidin domain receptor; ECM, extracellular matrix; HSPG, heparan sulfate proteoglycan; GH, growth hormone; IGF, insulin-like growth factor; IRF, interferon regulatory factor; MMP, matrix metalloproteinase; NFkappaB, nuclear factor-kappaB; Ptc-1, patched-1; TGF, transforming growth factor; TIMP, tissue inhibitor of metalloproteinases.
###end p 173
###begin p 174
Mammary gland-specific promoters
###end p 174
###begin p 175
###xml 11 16 <span type="species:ncbi:10090">mouse</span>
Transgenic mouse models of breast cancer metastasis
###end p 175
###begin p 176
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 7 8 7 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 8 11 8 11 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 25 26 25 26 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 86 87 86 87 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 113 117 113 117 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 117 121 <span type="species:ncbi:10090">mice</span>
###xml 153 157 <span type="species:ncbi:10090">mice</span>
aTumor t50 was reported; bmetastasis/tumor appearance but not incidence was reported; clung metastasis in all Plg-/- mice analyzed versus 56% in control mice; metastasis was dependent on tumor burden. HGF, hepatocyte growth factor; LN, lymph nodes.
###end p 176

